Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964906 | 1.00 | SLC22A6 (0.36) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL6463849 | 1.00 | SLC22A6 (0.36) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL19918393 | 0.82 | GABRR1 (0.33) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL19918389 | 0.82 | GABRR1 (0.33) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL3962591 | 0.80 | S1PR2 (0.36) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL27186030 | 0.80 | S1PR2 (0.36) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL3995049 | 0.80 | GABRP (0.35) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL3995651 | 0.80 | GABRP (0.35) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL28754981 | 0.80 | S1PR2 (0.36) | SLC22A6GABRR1LMNAS1PR2S1PR1 | |
| SCHEMBL3962147 | 0.79 | CACNA2D1 (0.38) | SLC22A6GABRR1LMNAS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-3087094-B1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | POLYPHOR AG (CH) | 2019-04-30 | — | — | US | disclosed |
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2019-02-21 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| EP-2334670-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | Almirall S.A. (ES) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC22A6 2807/4885GABRR1 335/4885LMNA 2246/4885 |
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | PTMS, ANPEP, DNPEP | SLC22A6 3779/4885GABRR1 4252/4885LMNA 2047/4885 |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | SERPINB1, ELANE, XPNPEP1 | SLC22A6 3076/4885GABRR1 4295/4885LMNA 570/4885 |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | S1PR2, S1PR3, S1PR1 | SLC22A6 3633/4885GABRR1 334/4885LMNA 4016/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | SLC22A6 3858/4885GABRR1 631/4885LMNA 2799/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | SLC22A6 3167/4885GABRR1 1181/4885LMNA 2161/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | SLC22A6 3858/4885GABRR1 631/4885LMNA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.